References
- Bai SB, Chen HX, Bao YX, et al. (2013). Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma. Asian Pac J Cancer Prev 14:3677–80
- Cho SJ, Horvai A. (2015). Chondro-osseous lesions of soft tissue. Surg Pathol Clin 8:419–44
- Chou AJ, Gorlick R. (2006). Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6:1075–85
- Deryugina EI, Quigley JP. (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9–34
- Duffy MJ, Maguire TM, Hill A, et al. (2000). Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2:252–7
- Franchi A, Santucci M, Masini E, et al. (2002). Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 95:1902–10
- Freije JM, Balbin M, Pendas AM, et al. (2003). Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 532:91–107
- Kallakury BV, Karikehalli S, Haholu A, et al. (2001). Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7:3113–19
- Kim TD, Song KS, Li G, et al. (2006). Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 6:211
- Kramárová E, Stiller CA. (1996). The international classification of childhood cancer. Int J Cancer 68:759–65
- Lin TS, Chiou SH, Wang LS, et al. (2004). Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol Rep 12:717–23
- Marina N, Gebhardt M, Teot L, et al. (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422–41
- Miller DP, Anderson RE, de Pablo JJ. (1998). Stabilization of lactate dehydrogenase following freeze thawing and vacuum-drying in the presence of trehalose and borate. Pharm Res 15:1215–21
- Nagase H, Woessner JF. (1999). Matrix metalloproteinases. J Biol Chem 274:21491–4
- Ohashi K, Nemoto T, Nakamura K, et al. (2000). Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 88:2201–9
- Price SJ, Greaves DR, Watkins H. (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276:7549–58
- Shellman YG, Makela M, Norris DA. (2006). Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines. Melanoma Res 16:207–11
- Stetler-Stevenson WG, Yu AE. (2001). Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 11:143–52
- Stetler-Stevenson WG, Liotta LA, Kleiner DE. (1993). Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:1434–41
- Tsai CH, Hsieh YS, Yang SF, et al. (2003). Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in human oral squamous cell carcinoma and the effect of protein kinase C inhibitors: preliminary observations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95:710–16
- Xu E, Lai M, Lv B, et al. (2004). A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun 324:999–1003